(Source: Genocea Biosciences Inc) October 8, 2014 Genocea Presents Complete Phase 1/2a Data for HSV-2 Immunotherapy at IDWeek After 12 months, GEN-003 shows durable reduction in genital lesions CAMBRIDGE, Mass.–(BUSINESS WIRE)– Genocea Biosciences, Inc. 28, 2013 /PRNewswire/ — Genocea Biosciences Inc., a clinical-stage company developing T cell vaccines to prevent and treat infectious diseases, announced today that its abstract describing an interim analysis of data from a Phase 1/2a clinical study of its lead candidate, GEN-003, has been selected as a late-breaking oral presentation at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2013). In addition to HSV-2, Genocea is utilizing this technology to develop preventive and therapeutic vaccines for Chlamydia, malaria, and Pneumococcus. The abstract is entitled “Novel Therapeutic Vaccine for Genital Herpes Reduces Genital HSV-2 Shedding.” Dr. Funds raised will support the continued development of Genocea’s two lead programs: GEN-003, a clinical-stage therapeutic vaccine candidate designed to reduce the frequency and severity of clinical outbreaks associated with moderate-to-severe Herpes Simplex Virus type 2 (HSV-2), and GEN-004, a preclinical vaccine candidate to prevent infections caused by Streptococcus pneumoniae. The study enrolled 143 volunteers with a history of moderate-to-severe recurrent HSV-2 infection at seven clinics in the United States. This platform may allow the firm to develop high quality vaccines for diseases in which T-cells are central to the control of the disease.
Subjects will be followed for 12 months after the last dose. It is estimated to infect more than 500 million people worldwide, and one out of six people age 14 to 49. Subjects will be followed for 12 months after the last dose. George Siber, M.D., most recently EVP and Chief Scientific Officer of Wyeth Vaccines, is a leading authority on vaccines. Malaria is one of the deadliest infectious diseases in the world. About HSV-2 Herpes simplex virus type 2 (HSV-2), the most common cause of genital herpes, is a sexually transmitted disease that is estimated to infect more than 500 million people worldwide, and one out of six people aged 15 to 49. The Imperial College London spin-out has put four products through Phase II and is about to take its lead candidate, a cat allergy vaccine, into Phase III.
(NYSE:MRK), GlaxoSmithKline plc (NYSE:GSK), Novartis Inc. (NYSE:NVS), Sanofi SA (NYSE:SNY), Pfizer Inc. coli/cLLO/OVA-pulsed DC injected in vivo induce cytotoxic T lymphocytes that can lyse a melanoma cell line that expresses OVA and suppress tumor growth following in vivo challenge. If approved, GEN-003 will have to compete with products already approved for the treatment of HSV-2, including oral antivirals like valacyclovir and famciclovir. There were 27,280 businesses that received angel funding, an increase of 3.7 percent. Clark also served as Chief Business Officer at Vanda Pharmaceuticals, a principal at Care Capital LLC, and in a variety of commercial and strategic roles at SmithKline Beecham (now GlaxoSmithKline). He holds a B.A.
from Harvard University and an M.B.A. For more information on Isconova: www.isconova.com. Isconova is a subsidiary of Novavax, Inc. Even if GEN-003 is approved, it faces a significant test in gaining commercial success, since treatments for HSV-2 already exist. There’s no guarantee that the medical community will accept the new treatment. Given these risks and the significant length of time before GNCA would be able to commercialize any of its product candidates, we do not recommend buying this IPO. Disclosure: I have no positions in any stocks mentioned, but may initiate a long position in GNCA over the next 72 hours.
I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.